Somatostatin analogues inhibit cancer cell proliferation in an SSTR2-dependent manner via both cytostatic and cytotoxic pathways

Oncology Reports

Volumn 21, Issue 2, 2009, Pages 379-386

  Zou, Yi ^a   Xiao, Xiaoping ^a   Li, Yueqin ^a   Zhou, Tianhong ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Cancer gene therapy; Somastostatin analogues; Somatostatin receptor 2

Indexed keywords

OCTREOTIDE; SOMATOSTATIN RECEPTOR 2; VAPREOTIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; ADENOVIRUS; DRUG EFFECT; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; METABOLISM; METHODOLOGY; NEOPLASM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; OCTREOTIDE; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOMATOSTATIN; TRANSFECTION;

EID: 62849112817     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000233     Document Type: Article

References (41)

1. Patel YC, Greenwood MT, Panetta R, Demchyshyn H, Niznik HB and Srikant CB: The somatostatin receptor family: a minireview. Life Sci 57: 1249-1265, 1995.
2. Corness JD, Demchyshyn LL, Seeman P, et al: A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS Lett 321: 279-284, 1993.
3. Bruno JF, Xu Y, Song J and Berelowitz M: Molecular cloning and functional expression of a brain-specific somato-statin receptor. Proc Natl Acad Sci USA 89: 11151-11155, 1992.
4. Demchyshyn LL, Srikant CB, Sunahara RK, et al: Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20. Mol Pharmacol 43: 894-901, 1993.
5. Carroll O, Lolait AM, Konig SJ and Mahan MLC: Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28. Mol Pharmacol 42: 939-946, 1992.
6. Panetta R, Greenwood MT, Warszynska A, et al: Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Mol Pharmacol 45: 417-427, 1994.
7. Kumar U, Sasi R, Suresh S, et al: Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: A quantitative double-label immunohistochemical analysis. Diabetes 48: 77-85, 1999.
8. Breder CD, Yamada YY, Yasuda K, Seino S, Saper CB and Bell GI: Differential expression of somatostatin receptor subtypes in brain. Neuroscience 12: 3920-3934, 1992.
9. Le Romancer M, Cherifi Y, Levasseur S, et al: Messenger RNA expression of somatostatin receptor subtypes in human and rat gastric mucosae. Life Sci 58: 1091-1098, 1996.
10. Rohrer L, Ranulf F, Bruns C, Buettner R, Hofstaedter F and Schule R: Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci USA 90: 4196-4200, 1993.
11. Yamada Y, Post SR, Wang K, Tager HS, Bell GI and Seino S: Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA 89: 251-255, 1992.
12. Hofland LJ and Lamberts SW: Somatostatin receptors and disease: role of receptor subtypes. Baillieres Clin Endocrinol Metab 10: 163-176, 1996.
13. Taboada GF, Luque RM, Bastos W, et al: Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156: 65-74, 2007.
14. Janson ET, Gobl A, Kälkner KM and Oberg K: A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 56: 2561-2565, 1996.
15. Kumar M, Liu ZR, Thapa L, Wang DY, Tian R and Qin RY: Mechanisms of inhibition of growth of human pancreatic carcinoma implanted in nude mice by somatostatin receptor subtype2. Pancreas 29: 141-151, 2004.
16. Vernejoul F, Faure P, Benali N, et al: Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res 62: 6124-6131, 2002.
17. Celinski SA, Fisher WE, Amaya F, Wu YQ, Yao Q, Youker KA and Li M: Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts. J Surg Res 115: 41-47, 2003.
18. Patel YC: Somatostatin and its receptor family. Front Neuroendocrinol 20: 157-198, 1999.
19. Lamberts SWJ, Krenning EP and Reubi J-C: The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12: 450-482, 1991.
20. Lamberts SWJ, Van Der Lely A-J and de Herder WW: Drug therapy: Octreotide. N Eng J Med 334: 246-254, 1996.
21. Weckbeker G, Raulf F, Stolz B and Bruns C: Somatostatin analogs for diagnosis and treatment of cancer. Pharmac Ther 60: 245-264, 1993.
22. Kvols LK and Woltering EA: Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs 17: 601-608, 2006.
23. Horiguchi K, Yamada M, Umezawa R, et al: Somatostatin receptor subtypes mRNA in TSH secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment. Endocr J 54: 371-378, 2007.
24. Pawlikowski M and Melen-Mucha G: Somatostatin analogs - from new molecules to new applications. Curr Opin Pharmacol 4: 608-613, 2004.
25. Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W and Lamberts SW: Pre-clinical and clinical experiences with novel somatostatin ligands:advantages, disadvantages and new prospects. Endocrinol Invest 28: 36-42, 2005.
26. Petersenn S: Efficacy and limits of somatostatin analogs. Endocrinol Invest 28: 53-57, 2005.
27. Guillermet-Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S and Susini C: Physiology of somatostatin receptors. Endocrinol Invest 28: 5-9, 2005.
28. Cattaneo AG, Taylor JE, Culler MD, Nisoli E and Vicentini LM: Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Lett 481: 271-276, 2000.
29. Sharma K, Patel YC and Srikant CB: Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10: 1688-1696, 1996.
30. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC and Patel YC: Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288: 154-157, 2000.
31. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS and Macke HR: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27: 273-282, 2002.
32. Liu HL, Huo L and Wang L: Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta Pharmacol Sin 25: 1380-1386, 2004.
33. Buscail L, Delesque N, Esteve JP, et al: Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 91: 2315-2319, 1994.
34. Klijn JG, Hoff AM, Planting AS, et al: Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 62: 627-630, 1990.
35. Kohlfuerst S, Igerc I, Gallowitsch HJ, Gomez I, Kresnik E, Matschnig S and Lind P: Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases? Thyroid 16: 1113-1119, 2006.
36. Taboada GF, Luque RM, Neto LV, et al: Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 158: 295-303, 2008.
37. Stirnweiss J, Hartrodt B, Greksch G, Stürzebecher U, Böhmer FD, Neubert K and Liebmann C: Tyr-c[D-Orn-Tyr(Bzl)-Pro-Gly]: a novel antiproliferative acting somatostatin receptor agonist with mu-opioid receptor-sensitizing properties. Br J Pharmacol 140: 13-22, 2003.
38. Ren SG, Taylor J, Dong J, Yu R, Culler MD and Melmed S: Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 88: 4239-4245, 2003.
39. Yoshihara A, Isozaki O, Hizuka N, et al: Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy. Endocr J 54: 133-138, 2007.
40. Yang JY, Zong CS, Xia W, et al: ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10: 138-147, 2008.
41. Nelson WJ and Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483-1487, 2004.